S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

NRx Pharmaceuticals Rises 9.8% as Quarterly Loss Narrows

NRx Pharmaceuticals shares climbed 9.8% to $2.36 after the clinical-stage drugmaker reported a smaller third-quarter loss than a year earlier and beat analysts’ expectations. The stock remains down 13% year to date.

NRx Pharmaceuticals Rises 9.8% as Quarterly Loss Narrows

The company reported a net loss of $2.2 million, or 5 cents a share, compared with $5.9 million, or 27 cents a share, in the same quarter last year. Analysts polled by FactSet had expected a loss of 21 cents a share.

Net patient service revenue rose nearly five-fold to $1.2 million from $242,000 a year earlier, driven by growth at Hope Therapeutics clinics. That result fell short of Wall Street’s $1.3 million revenue estimate. NRx Pharmaceuticals, which is based in Florida, operates six Hope Therapeutics clinics focused on interventional psychiatry.

The company said the Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine in October, ahead of the Nov. 10 goal date. NRx began selling the drug the week of Nov. 9. The approval was the company’s first for a drug.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!